In a murine melanoma model, the use of the PPARα agonist fenofibrate increased FA catabolism and subsequently enhanced the tumor-killing activity of CD8+ T-cells in the TME, significantly enhancing anti-tumor efficacy when combined with in vivo PD-1 blockade therapy [128]. Here, CD8A is linked to melanoma.